Autism spectrum disorders (ASDs) are highly heritable, yet relatively few associated genetic loci have been replicated. Copy number variations (CNVs) have been implicated in autism; however, the majority of loci contribute to less than 1% of the disease population. Therefore, independent studies are important to refine associated CNV regions and discover novel susceptibility genes. In this study, a genome-wide SNP array was utilized for CNV detection by two distinct algorithms in a European ancestry case-control dataset. We identify a significantly higher burden in the number and size of deletions, and disrupting more genes in ASD cases. Moreover, eighteen deletions larger than 1Mb were detected exclusively in cases, implicating novel regions at 2q22.1, 3p26.3, 4q12, and 14q23. Case-specific CNVs provided further evidence for pathways previously implicated in ASDs, revealing new candidate genes within the GABAergic signaling and neural development pathways. These include DBI, an allosteric binder of GABA receptors, GABARAPL1, the GABA receptor-associated protein, and SLC6A11, a postsynaptic GABA transporter. We also identified CNVs in COBL, deletions of which cause defects in neuronal cytoskeleton morphogenesis in model vertebrates, and DNER, a neuron specific Notch ligand required for cerebellar development. Moreover, we found evidence of genetic overlap between ASDs and other neurodevelopmental and neuropsychiatric diseases. These genes include glutamate receptors (GRID1, GRIK2 and GRIK4), synaptic regulators (NRXN3, SLC6A8, and SYN3), transcription factor (ZNF804A), and RNA binding protein FMR1. Taken together, these CNVs may be a few of the missing pieces of ASD heritability and lead to discovering novel etiological mechanisms. 
Introduction
Autism spectrum disorders (ASDs) are among the most heritable of neurodevelopmental disorders (1) (2) (3) (4) . Given their strong genetic component, gene discovery in ASDs has been the focus of research for the past decade. To date, no single gene has been shown to account for a majority of ASD susceptibility. The limited success of gene discovery has been attributed to the genetic heterogeneity and phenotypic variability of ASDs. In fact, hundreds of candidate genes have been implicated. These candidates include rare variations with large effect sizes in syndromic forms of ASD including tuberous sclerosis (TSC1 and TSC2) (5, 6) , Rett syndrome (MECP2) (7) , and Phelan-McDermid syndrome (SHANK3) (8) . In addition, despite fruitful genome-wide association studies (GWAS) in many other genetic disorders (9) , this approach in studying ASDs has revealed only a few associated common alleles with small effect sizes, many of which have not yet been replicated in independent studies (10) (11) (12) (13) (14) .
Therefore, studying low frequency variants with variable expression or reduced penetrance may be necessary to identify predisposing alleles.
Among aberrations of interest are copy number variations (CNVs). They represent a significant source of genetic diversity and contribute to disease susceptibility for several neurobehavioral phenotypes including ASDs, mental retardation, and schizophrenia (15) (16) (17) (18) (19) (20) (21) (22) . The accelerated discovery of CNVs coinciding with ASDs has provided evidence of their involvement in ASD etiology, although individual CNVs generally account for less than 1% each of attributable risk (23) . Some CNVs have pleiotropic effects that associate with susceptibility to several neuropsychiatric disorders (12, 20, (24) (25) (26) (27) (28) (29) (30) (31) (32) . Therefore, careful characterization of CNVs in ASD patients represents an important aspect of genetic research.
Gene-set enrichment analyses from both GWAS (33) and CNV studies (20, 31) have revealed functional gene families and molecular pathways likely to contribute to the pathogenesis of ASDs.
However, the gene-set enrichment statistical framework, particularly as applied to CNVs, is limited and potentially confounded (34) . A joint analysis of two autism GWAS datasets implicated neuronal growth and axon guidance as well as cytoskeletal regulation and neuronal cell signaling (33) . Among CNV gene set analyses, the ubiquitin pathway and genes involved in neuronal cell adhesion have been consistently by guest on http://hmg.oxfordjournals.org/ Downloaded from implicated in ASDs (20, 31) . A recent CNV study from the Autism Genome Project (AGP) identified an enrichment of CNVs disrupting GTPase/Ras signaling genes, and confirmed the involvement of genes responsible for cellular proliferation, projection and motility (20) . Moreover, a recent study utilizing pathway analysis of de novo CNVs has implicated genes directing synapse development, axon targeting, and neuron motility in autism risk (35, 36) . Therefore, given the heterogeneous nature of ASDs and their potential genetic causes, disruption of additional genes in these and related molecular pathways are expected to be involved in ASDs.
Further studies are required not only to refine our understanding of the roles of previously isolated genes and regions in ASDs but also to identify novel candidates within implicated molecular pathways. In this study, we used a combined family and case control Caucasian dataset to support previously associated ASD CNVs and identify unique, large and potentially pathogenic deletions as well as novel genes within molecular pathways previously connected to ASDs.
Results

Global CNV burden analysis
In an attempt to recognize overall differences in CNVs between cases and controls, high confidence CNVs from 813 unrelated ASD cases and 592 control Caucasian samples (Table 1) were included in the CNV burden analysis following extensive CNV QC filtering (Table 2) . To eliminate potential biases from various DNA sources and gender between cases and controls, burden analysis for deletions and duplications was performed separately and only for autosomes (see details in Materials and Methods).
We detected a significantly higher burden in the number and size of deletions in cases for both the total and rare (<1% frequency) CNV sets ( 
CNVs identified in previously implicated ASD regions
To identify specific CNVs which may contribute to autism risk, we first examined CNVs in eight well-established ASD associated regions (1q21, 7q11.23, 15q13, 15q11-13, 16p11.2, 17p11.2, 22q13.3 and 22q11.21). We detected and validated nine CNVs from these regions that overlap at least 50% of their length with regions previously implicated in autism risk within our dataset including reciprocal duplications and a deletion at 16p11.2. To determine whether these CNVs were concordant with disease, we determined the inheritance status in all families and segregation of variants within multiplex ASD families using the genotyping data from available family members and qPCR (Table 3 
Identification of large, novel deletions
Since no deletions greater than 1Mb were found in controls, we examined this subset of large and possibly pathogenic structural variations identified exclusively in cases. Eighteen such deletions ranging from 1.02 to 7.31 Mb were detected in ten simplex families and six multiplex families (Table 4) . Familial genotyping and CNV data as well as qPCR (Supplemental Figure 3) validation revealed that seven of the eighteen deletions were de novo and ten were inherited (5 paternally, 5 maternally) while the inheritance status for one CNV could not be determined. Five of the eighteen deletions overlapped with wellestablished ASD regions reported in Table 3 . Five others have been identified in autistic patients in studies by the AGP (20, 37) . Independent autism CNV studies identified deletions at 5q35.3 (38) , 10p15.2 (39), 10q11. 22-23 (29) , and Xp22.31 (40) that physically overlap at least half of a CNV found in our data. 
Identification of potentially pathogenic CNVs and candidate genes from case-specific CNVs
Pathway enrichment analysis of case-specific CNVs did not reveal any gene ontology or KEGG pathways which were significantly overrepresented in our CNV set. Therefore, we evaluated our data to enrich for potentially pathogenic CNVs in ASDs. To do this, case-unique CNVs were selected. A total of 3855 CNVs met this criterion. Genes located within these CNV regions were compiled and their functions assessed by literature review. Firstly, CNVs in several genes previously associated with autism risk including deletions in A2BP1, APBA2, GRIN2B, and NRXN3 were identified in this way. Secondly, several novel candidate genes in molecular pathways or genetic networks implicated in autism etiology were identified including genes in the GABAergic signaling pathway (DBI, GABARAPL1, and SLC6A11) and genes acting in neural development and function (COBL, DNER, and GDNF). In addition, our caseunique CNVs revealed several loci implicated in other neuropsychiatric disorders including Fragile X syndrome (FMR1), mental retardation (GRIK4), obsessive compulsive disorder (GRIK2), and schizophrenia (GRID1, NRXN3, SLC6A11, SYN3, TIMP3, and ZNF804A). These CNVs were validated with TaqMan copy number assays and their inheritance status determined using familial genotyping data ( 
Discussion
In the present study, we identified several potentially pathogenic candidate regions and genes that may contribute to ASD etiology. At the global level, our results replicate a recent study which indicated an overall increase in the burden of rare genic deletions in ASD individuals (20) . However, while the AGP reported an increase in rare deletions in affected individuals, our study finds that ASD cases have significantly larger deletions and more overall deletions (20) . These differences may reflect dataset specific variation in factors such as the ASD diagnostic criteria, ratios of simplex to multiplex families, regional or other sampling biases, as well as array platform-and DNA source-origin biases.
Beyond identifying a higher overall burden of deletions in ASD cases compared to controls, we detected and validated CNVs at eight regions that have been previously associated with autistic traits; 1q21, 7q11.23, 15q13, 15q11-13, 16p11.2, 17p11.2, 22q13.3 and 22q11.21 (28, (41) (42) (43) (44) (45) (46) (47) . While many of these have been previously implicated by classical cytogenetic techniques, recent large scale CNV studies using both genotyping and array CGH have also isolated these same CNVs as associated with autism (35, 48, 49) . In our data, we identified two cases overlapping a classic cytogenetic aberration associated with autism, the 5Mb maternally inherited 15q11-13 duplication. This duplication, which occurs in approximately 1% of all autism cases (44, 50) , falls between low copy repeats on chromosome 15 and duplicates many genes including three GABA receptors. We also detected CNVs within regions known to be syndromic causes of autism; two duplications and one de novo deletion of 550kb on 16p11.2 (51) (28, 30) and two duplications of 900kb on 1q21.1 (41), both of which are recurrent CNVs due to their location between segmental duplications. In addition, a 3Mb de novo deletion on 17p11.2, which deletes RAI1, has been previously implicated in both Smith-Magenis syndrome and an autisitic syndrome (52).
Additionally, one case carrying a complex 1.4Mb duplication between segmental duplications at 7q11.23 partially overlaps the region deleted in Williams-Beuren syndrome in which duplications have previously been associated with autism (42, 53) . Finally, another individual carries a the same 4Mb deletion on 22q13.3 that causes Phelan-McDermid syndrome and contains the autism gene SHANK3 (54, 55) .
Moreover, several large CNVs that affect previously reported candidate genes were also identified. A by guest on http://hmg.oxfordjournals.org/ Downloaded from 1Mb duplication at 22q11.21 encompasses the entire COMT gene that has been implicated in developmental delay and autism (45, 47, 56, 57) . Two patients carry deletions of 15q13.1-3, thereby removing either the entire gene or several exons of CHRNA7, deletions of which have been shown to be involved in developmental delay, mental retardation, and epilepsy (43, 58, 59) . While all of these CNVs have strong evidence for being causative of ASDs, discordance within multiplex families has been previously noted for duplications and deletions on 16p11.2 (30, 60) and duplications of 22q11.21 (61) .
Given such evidence, the lack of perfect concordance between these established CNVs and disease in some of our multiplex families (Supplementary Figure 1) suggests that there are probably additional genetic components contributing to disease in these families.
Besides the five large deletions discussed above (two at 15q13.1, 15q13.1-3, 17p11.2, and 22q12. [31] [32] [33] , thirteen other deletions greater than 1Mb were observed exclusively in cases. These are of particular interest due to their possible pathogenic effect in neuropsychiatric diseases (62) . Nine of these twelve have been identified as ASD candidate regions in previous CNV studies (20, 29, (37) (38) (39) (40) . The detection of deletions in these regions (5q23.1, 5q35.3, 10p15.2, 10q11.22-23, 13q12.12, 13q33.1, two at 17p12, and Xp22.31) lend further support to their harboring ASD pathogenic variations. Moreover, the mechanism of formation of these deletions, with the exception of 5q23.1, is predicted to be nonallelic homologous recombination due to the presence of flanking segmental duplications. Interestingly, four large deletions (2q22.1, 3p26.3, 4q12, and 14q23) are not flanked by known genomic instability elements and represent potentially novel contributors to autism etiology. A de novo deletion on 2q22.1 includes HNMT, a gene which regulates histamine metabolism in the brain and has been previously implicated in anxiety and alcoholism (63) . We also identify a paternal deletion on 3p26.3 that deletes the neural adhesion molecules CHL1 and CNTN6, which is near a previously reported autism associated CNV (64) .
Furthermore, genes involved in circadian rhythms have been implicated in autism (65) and a new candidate, CLOCK, was removed in a de novo deletion on 4q12. Finally, pleiotropic effects of these novel, large deletions were found in an autistic patient with spherocytosis carrying a de novo 14q23 by guest on http://hmg.oxfordjournals.org/ Downloaded from deletion that removes several neurodevelopmental genes including CHURC1, MTHFD1, and PLEKHG3 as well as the red blood cell structural gene SPTB (66) . As such, these substantial deletions point toward dysfunction of neuron cell structure and adhesion as well as circadian regulation as contributors to autism.
In an attempt to find potentially pathogenic genes contributing to autism risk, we first used a pathway enrichment strategy to identify functional molecular networks which were overly represented by CNVs in cases. However, we did not identify a statistical overrepresentation of any category. While large scale CNV studies report enrichment in their datasets (36, 49) , other studies have suggested that since the causes of autism are quite diverse, no singular mechanism or pathway is likely to explain the entire spectrum of risk (67) . Therefore, we chose to search for novel candidate genes or gene clusters in rare, case-unique CNVs. This analysis revealed several genes previously associated with autism risk including A2BP1 (68), APBA2 (69), GRIN2B (70, 71) , NRXN3 (72) , and SHANK3 (73, 74) . Of particular interest among these genes is the splice factor A2BP1 which has not only been associated with autism but regulates the expression of many genes misregulated in post-mortem autism brains (75) . Novel members of pathways previously implicated in autism include three genes in the GABAergic signaling pathway Beyond the GABAergic system, rare CNVs disrupting genes which play a role in neural development have been implicated in autism etiology (20) . We identified case-unique CNVs that traverse genes affecting these processes. Our findings further implicate genes involved in neuronal cytoskeletal formation as we find a CNV which deletes exons 2-5 of COBL, knockouts of which show severe defects in neural cell cytoskeleton morphogenesis (83) . In addition, our CNV analyses implicated signaling factors involved in neural development. We detected a duplication of exons 2-6 of DNER, a neuron specific Notch ligand required for cerebellar development (84, 85) and deletion of the entire GDNF gene, by guest on http://hmg.oxfordjournals.org/ Downloaded from a growth factor which fosters neuronal cell survival (86) . The discovery of case-unique CNVs within these novel genes in previously associated molecular networks supports the importance of these pathways in autism as well as implicating new potential genetic risk factors, making them attractive candidates for follow-up.
Our data also identifies several genes with neuronal functions that have been previously connected to other neuropsychiatric diseases. Such genetic overlap has been noted and previously discussed (87). We found CNVs in genes associated with schizophrenia including two glutamate receptors, the first deleting the entire GRIK2 gene (88, 89) and the second being an intronic deletion in GRID1 (90), a duplication of the first five exons of the synaptic protein SYN3 (91), a deletion of two exons of the neuronal adhesion molecule NRXN3, and duplication of the zinc finger ZNF804A (92) . We also found CNVs in genes involved in other neurological disorders. The neurotransporter SLC6A8 has been implicated in mental retardation (93) and we identified a deletion of its first 8 exons. Expansions in the 5' untranslated region of FMR1 are known to cause both Fragile X syndrome and Fragile X-associated tremor/ataxia syndrome (94) and we found a deletion of this entire gene. The overlap of these genes with other neuropsychiatric diseases suggests an etiological connection between these disorders and ASDs and points to the disruption of these genes as having broad neurological phenotypes.
In conclusion, we found there to be a significantly higher burden in the number and size of deletions carried by ASD individuals as compared to controls. Among the CNVs identified were several that overlapped with well-established autism associated regions and candidate genes, further supporting their roles in autism etiology. Moreover, we isolated four large, novel deletions on 2q22.1, 3p26.3, 4q12, and 14q23 that include new genes and regions linked to ASDs. These findings provide further evidence for the involvement of previously molecular pathways, including the GABAergic signaling and neurodevelopmental pathways, while revealing several novel genes that may lead to new etiological mechanisms.
Material and methods
Ascertainment of autism spectrum disorder families
This study is part of the Collaborative Autism Project (CAP), for which a total of 1084 simplex and multiplex autism families were ascertained with a range of self-reported ethnicities through clinical groups at the John P. Hussman Institute for Human Genomics at the University of Miami (HIHG, Miami, FL), the University of South Carolina (Columbia, SC), and the Center for Human Genetics Research at Vanderbilt University (Nashville, TN). Participating families were enrolled via support groups, advertisements, and clinical and educational settings. All participants and families were ascertained using a standard protocol approved by the appropriate Institutional Review Boards. Written informed consent was obtained from parents as well as from minors who were able to give informed consent; for individuals unable to give consent due to age or developmental problems, assent was obtained whenever possible. Core inclusion criteria were as follows: (1) problems (e.g., visual impairment or hearing loss), significant motor impairments (e.g., failure to sit by 12 months or walk by 24 months), or who had a previously identified metabolic, genetic, or progressive neurological disorders.
Ascertainment of pediatric controls
896 healthy children, including 664 self-reported Caucasians, were recruited as pediatric controls from two centers. 565 individuals aged 4 to 21 years old were sampled through the John. P. Hussman Institute for Human Genomics (Miami, FL). Participants were screened for eligibility by a series of preliminary questions to determine whether the individual either had been diagnosed with or had a parent or sibling with a developmental, behavioral, neurological or other disability or physical conditions. If none of those conditions were present, parents of young children or the participants were informed and signed the informed consent and completed the Social Communication Questionnaire (98) to screen for potential ASDs. The remaining 331 controls were part of a preterm birth study. Cord blood was collected at the Centennial Medical Center (Nashville, TN) from women aged from 18 to 40 years old with term pregnancies (> 37 weeks gestation), live, singleton births.
Genotyping
Genomic DNA was purified from whole blood, cell line and saliva samples using Puregene chemistry on the Qiagen Autopure LS according to standard automated Qiagen protocols (Qiagen, Valencia, CA). DNA samples were quantitated via the ND-8000 spectrophotometer and DNA quality was evaluated by gel electrophoresis on a 0.8% agarose gel. The concentration for all qualified samples was normalized to 50 ng/l and samples were arrayed in Matrix 0.5ml 2D barcoded tubes in racks of 96.
Sample identity was confirmed by genotyping eight SNPs using TaqMan allelic discrimination assays (Applied Biosystems, Foster City, CA) and assessing for concordance with historical data. All recruited participants, available siblings and parents, and recruited controls were genotyped using either Illumina's were excluded from analysis and a GenCall cutoff score of 0.15 was used for all Infinium II ® products.
Genotyping and CNV quality control (QC)
Out of 1084 autistic families and 896 pediatric controls, samples with a genotype call rate >97% and only cases without excessive Mendelian inconsistencies within the pedigree (>2% among all tested SNPs) were processed further for CNV QC. Following this family-based sample quality control, 1063 families, encompassing 1301 ASD cases, remained for CNV calling. The signal intensity QC used the parameters generated in the CNV detection program PennCNV (99) . Samples with less than 0.30 standard deviation (SD) of the normalized intensity Log R ratio (LRR) and a correlation of LRR to wave model ranged between -0.2<X<0.4 were included. The remaining samples were examined further and excluded if the total number of CNV calls per individuals exceeded three standard deviations from the mean number of CNV calls. Thus, only samples with a total CNV call count < 142 were included. A total number of 1174 cases, including 184 affected siblings from multiplex families, and 771 controls fit the above criteria suggesting that overall data quality would not remove a significant portion of our sample.
Next, unrelated cases and controls were selected for population stratification checking. To maintain independence of this dataset, only one ASD case per family was analyzed. Therefore, 184 affected siblings were removed from the initial CNV analysis, but later used to examine concordance in multiplex families. In addition, two samples were taken out due to overlap with the previously published Autism Genome Project (AGP) dataset (20) . One trisomy X female and one duplicated Xp male were also removed. These steps left 986 cases and 771 controls for population stratification analysis. We performed clustering with principle component analysis using the EIGENSTRAT program (100). In order to recognize independent ethnicity clusters in our data, we combined it with HapMap genotyping data from ten ethnicities. A total of 813 cases and 592 controls clustered with CEU, and remained for the final casecontrol CNV analysis. These included 260 cases from multiplex families, 483 from simplex families, and 62 from families with siblings having autistic-like traits without a confirmed ASD diagnosis and 8 from by guest on http://hmg.oxfordjournals.org/ Downloaded from families with MZ twins. 649 of 813 cases had both parents survive all QC steps to be used in the familybased trio function within PennCNV to determine whether CNVs were inherited or de novo.
High confidence CNV identification
The QuantiSNP (101) and PennCNV (99) algorithms were both utilized for CNV identification.
Intensity wave artifacts across the genome, which interfere with accurate inference of CNVs, were corrected by both programs. The Bayesian factor (BF) scores provided by QuantiSNP were calculated to reflect the accuracy of a CNV call. A BF score of 15 was used as a cutoff to include only reliable copy number alterations. Finally, high confidence CNV calls were defined as those called by both algorithms in a person and overlapped for at least 20% of their length.
CNV filtering
PLINK (1.0.7 version) (102) was employed to remove CNVs that overlapped for at least 50% of their length with segmental duplication regions (downloaded from the UCSC genome browser, http://genome.ucsc.edu), peri-centromeric regions (recommended by PennCNV), pseudoautosomal regions on the X chromosome, and CNVs containing more than 70% GC content. CNVs were only selected for analysis that spanned at least 5 SNPs and had a length of more than 30kb as these filtering criteria in a previous large scale study achieved a validation rate of greater than 90% (49) . Rare CNVs were defined as CNVs with a frequency of less than 1% in the entire case control dataset. In addition, case-unique CNVs that did not overlap more than 50% of their length with any control CNVs identified in the CHOP CNV database (http://cnv.chop.edu/) were used to compile a list of potential candidate genes for validation.
Bias checking
Since the total number of CNVs per individual could be influenced by gender, genotyping platform, or DNA source, several comparisons were made to evaluate these potential biases in cases and controls. In our dataset, there is a distinct male to female bias in cases (707/106) as compared to controls (289/303). While females have significantly more CNVs identified on the X chromosome, no difference was found on autosomes (p=0.903 for controls; p=0.795 for cases). We also examined the potential 
CNV validation
We selected a subset of candidate genes and regions for validation by real time PCR. These included four distinct categories; (1) regions or genes previously reported to carry ASD specific CNVs, 
CNV analysis
Analysis was carried out in two datasets: (1) the entire CNV set and (2) the rare CNV set (frequency <1%). The genome-wide CNV burden was assessed in deletions and duplication separately due to the potential bias identified from genotyping array differences on duplications. In addition, the burden analysis was carried out in autosomal CNVs only due to a skewed male to female ratio in cases as compared to controls. Significance of the mutational burden comparisons was determined via permutation (100,000 time, one-sided test) using PLINK (version 1.0.7). Pathway enrichment for CNV sets were performed using WebGestalt (http://bioinfo.vanderbilt.edu/webgestalt/). The CNV lists were uploaded using the Illumina Omni-1 Quad SNP gene list as the background gene list. Enrichment was performed using a hypergeometric test requiring at least two genes in a pathway with multiple test correction proposed by Benjamini & Hochberg (104) . @ number of affected siblings in the family with the CNV/total affected siblings $ number of unaffected siblings in the family with the CNV/total unaffected siblings * deletions in well-established autism candidate regions -reported in Table 3 # ND: not determined Non-autism diagnosis indicated in parenthesis 
